Dr. Wise on Unmet Needs in the Standard of Care in Prostate Cancer

Video

In Partnership With:

David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.

David R. Wise, MD, PhD, assistant professor, the Department of Medicine, the Department of Urology, the NYU Grossman School of Medicine, NYU Langone Health, discusses unmet needs in the standard of care in prostate cancer.

Several options comprise the current standard of care in prostate cancer, including hormone suppression as the backbone of treatment, Wise says. However, multiple studies have now showed that treatment should be intensified with the addition of a second agent beyond androgen suppression, such as docetaxel (Taxotere), abiraterone acetate (Zytiga), apalutamide (Erleada), or enzalutamide (Xtandi), Wise explains.

Moreover, a subset of patients with low-volume, metastatic prostate cancer can be intensified with low-dose, prostate-directed radiation therapy, Wise continues. The next important step in research will involve examining the benefit of further intensifying treatment, Wise concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic